Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer

British Journal of Cancer

Volumn 91, Issue 1, 2004, Pages 129-140

  Ahmed, N ^a   Barker, G ^a   Oliva, K T ^a   Hoffmann, P ^b   Riley, C ^a   Reeve, S ^c   Smith, Al ^c   Kemp, B E ^b   Quinn, M A ^a   Rice, G E ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b St Vincent's Public Hospital   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Biomarkers; Haptoglobin; Haptoglobin 1 precursor (HAP1); Ovarian cancer; Proteomics

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; EPITOPE; GLYCOPROTEIN; HAPTOGLOBIN; HAPTOGLOBIN 1 PRECURSOR; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; POLYACRYLAMIDE GEL; PROTEIN A; PROTEIN PRECURSOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACIDITY; ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; ELECTROSPRAY; EPITHELIUM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISOELECTRIC FOCUSING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYXOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; REACTION TIME; STATISTICAL SIGNIFICANCE; STROMA; TIME OF FLIGHT MASS SPECTROMETRY; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; BLOOD; CANCER STAGING; CASE CONTROL STUDY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY;

CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HAPTOGLOBINS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTEIN PRECURSORS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 3342986675     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601882     Document Type: Article

References (32)

1. Ahmed N, Barker G, Oliva K, Garfin D, Talmadge K, Georgiou H, Quinn M, Rice G (2003) An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 3: 1980-1987
2. Bastani B, Chu N (1995) Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. Am J Nephrol 15: 468-472
3. Beutler E, Gelbart T, Lee P (2002) Haptoglobin polymorphism and iron homeostasis. Clin Chem 48: 2232-2235
4. Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329: 1550-1559
5. Devarbhavi H, Kaese D, Williams AW, Rakela J, Klee GG, Kamath PS (2002) Cancer antigen 125 in patients with chronic liver disease. Mayo Clin Proc 77: 538-541
6. Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P (2000) Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem 33: 579-583
7. Dobryszycka W, Katnik-Prastowska I, Gerber J, Lemanska K, Utko K, Rozdolski K (1999) Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary. Arch Immunol Ther Exp (Warsz) 47: 229-236
8. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51: 15-36
9. Hanley JM, Heath EC (1985) A novel proteolytic activity in serum processes rat prohaptoglobin. Arch Biochem Biophys 239: 404-419
10. Haugen TH, Hanley JM, Heath EC (1981) Haptoglobin. A novel mode of biosynthesis of a liver secretory glycoprotein. J Biol Chem 256: 1055-1057
11. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353: 1207-1210
12. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW, Mok SC (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287: 1671-1679
13. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 1,8-31
14. Lloyd KO, Yin BW (2001) Synthesis and secretion of the ovarian cancer antigen CA 125 by the human cancer cell line NIH:OVCAR-3. Tumour Biol 22: 77-82
15. Luo LY, Bunting P, Scorilas A, Diamandis EP (2001) Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 306: 111-118
16. Mackey SE, Creasman WT (1995) Ovarian cancer screening. J Clin Oncol 13: 783-793
17. Misumi Y, Tanaka Y, Ikehara Y (1983) Biosynthesis, intracellular processing and secretion of haptoglobin in cultured rat hepatocytes. Biochem Biophys Res Commun 114: 729-736
18. Mogensen O (1992) Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44: 207-212
19. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW (2001) Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93: 1458-1464
20. Mueller WK, Handschumacher R, Wade ME (1971) Serum haptoglobin in patients with ovarian malignancies. Obstet Gynecol 38: 427-435
21. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577
22. Scholler N, Fu N, Yang Y, Ye Z, Goodman GE, Hellstrom KE, Hellstrom I (1999) Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 96: 11531-11536
23. Schreiber G, Urban J (1978) The synthesis and secretion of albumin. Rev Physiol Biochem Pharmacol 82: 27-95
24. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, Hassell L, Baldwin RL, Karlan BY, Hood L (1999) Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238: 375-385
25. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harlozinska A (2002) Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer 95: 1886-1893
26. Silverberg S (2000) Histopathologic grading of ovarian carcinoma: a review an proposal. Int J Gynecol Pathol 19: 7-15
27. Thompson S, Cantwell BM, Matta KL, Turner GA (1992a) Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer. Cancer Lett 65: 115-121
28. Thompson S, Dargan E, Turner GA (1992b) Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett 66: 43-48
29. Wassell J (2000) Haptoglobin: function and polymorphism. Clin Lab 46: 547-552
30. Wilson NL, Schulz BL, Karlsson NG, Packer NH (2002) Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins. J Proteome Res 1: 521-529
31. Woolas RP, Oram DH, Jeyarajah AR, Bast RC, Jacobs IJ (1999) Ovarian cancer identified through screening with serum markers but not by pelvic imaging. Int J Gynecol Cancer 9: 497-501
32. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, Horick NK, Licklider LJ, Schorge JO, Berkowitz RS, Mok SC (2003) Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 9: 2904-2911